Skip To Main Content
Jack Khouri on Muck Rack

Jack Khouri

Cleveland
As seen in: Nature, Wiley Online Library, Frontiers, MDPI, JAMA Oncology, Annals of Internal Medicine, Healio, Future Medicine, ONCOLOGY journal, OncLive and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jack

Contact Jack, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma

|
By Utkarsh Goel, Diana Basali, Louis Williams, Sandra Mazzoni, Jason Valent, Shahzad Raza, Faiz Anwer, Jack Khouri, Catalin Dragomirescu, Roy Chedid
| Nature Verified
Dear Editor, Chimeric Antigen Receptor T cell (CAR-T) therapy induces heterogenous depth of response and response kinetics in relapsed/refractory multiple myeloma (RRMM). E.g., in the KARMMA-1 trial, the median time to first response was 1 month (range 0.5–8.8), while the median time to complete response or better was also variable (median 2.8 months, range 1–11.8) [1]. This post-infusion disease behavior may not be fully captured by pre-infusion risk-stratification approaches alone [2,3,4,5,6].
Open in Who Shared Issue with article?

Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort

|
By Hossam Ali, Sandra Mazzoni, Utkarsh Goel, Jack Khouri, Faiz Anwer, Louis Williams, Christy Samaras, Beth Faiman, Kimberly Hamilton, Joslyn Rudoni, Mikhaila Rice, Jonathan Kissam, Cynthia Scott, Saveta Mathur, Alexandra Varney McDonald, Tara Roy, Julie Bevacqua, Marcelo C. Pasquini, Jason Valent, Shahzad Raza, Diana Basali, Willem Van Heeckeren
| Nature Verified
Patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment (RI) are considered a high-risk group frequently excluded from clinical trials. Patients with RI have a higher risk of disease progression or death compared to those without RI (relative risk (RR): 1.20 [1.003–1.431]) [1]. RI is a negative prognostic factor linked to early mortality, shorter overall survival (OS), and greater treatment-related toxicity.
Open in Who Shared Issue with article?

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

|
By Andrew J. Portuguese, James Davis, Shahzad Raza, Omar Castaneda Puglianini, Ciara L Freeman, Melissa Alsina, Corbin Wright, Brandon Blue, Rachid Baz, Kenneth H Shain, Utkarsh Goel, Jack Khouri, Faiz Anwer, Hossam Ali, Oren Pasvolsky, Mahmoud R. Gaballa, Damian Mikulski, Lindsay Fogel, Eli Zolotov, Aishwarya Sannareddy, Aimaz Afrough, Larry D. Jr, Kelley Julian, Danai Dima, Rahul Banerjee, Emily Liang, Raffaella Cassano, Megan Herr Verified, Hamza Hassan, Leyla O. Shune, Jeries Kort, Shonali Midha, Omar Nadeem, Surbhi Sidana, Yi Lin, Frederick Locke, Doris Hansen, Douglas Sborov, Noa Biran, Ariel Grajales-Cruz, Hector Garcia-Pleitez
| Nature Verified
Abstract Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies.
Open in Who Shared Issue with article?
See all 55 licensed articles (57 Total)